1. Neurological Disease

Neurological Disease

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-18137
    PF-04995274 1331782-27-4 99.95%
    PF-04995274 is a potent, high-affinity, orally active and partial serotonin 4 receptor (5-HT4R) agonist. PF-04995274 has an EC50 range of 0.26-0.47 nM for human 5-HT4A/4B/4D/4E (Ki range of 0.15-0.46 nM), and has an EC50 range of 0.59-0.65 nM for rat 5-HT4S/4L/4E (Ki of 0.30 nM for rat 5-HT4S). PF-04995274 is brain penetrant and can be used for cognitive disorders associated with Alzheimer's disease.
    PF-04995274
  • HY-18663
    CP-465022 199655-36-2 98.47%
    CP-465022 is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC50 of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes.
    CP-465022
  • HY-18670
    HQ-415 430462-93-4 98.05%
    HQ-415 is a biologically active metal chelator related to Clioquinol (HY-14603), with an EC50 of 15 μM.
    HQ-415
  • HY-18671
    BoNT-IN-1 694443-03-3 99.17%
    BoNT-IN-1 is an effective inhibitor of botulinum toxin type A light chain (BoNTA LC), with an IC50 value of 0.9 μM.
    BoNT-IN-1
  • HY-19134
    EMD 56551 133109-86-1 98%
    EMD 56551 is a potent and selective 5-HT1A receptor agonist. EMD 56551 exerts anxiolytic activity.
    EMD 56551
  • HY-19271
    NS-2710 184220-36-8 99.21%
    NS-2710 is a high-efficacy GABAAα3 agonist with a Ki of 9.2 nM. NS-2710 can be used for anxiety research.
    NS-2710
  • HY-19366
    Nav1.7-IN-2 1332295-35-8 99.81%
    Nav1.
    Nav1.7-IN-2
  • HY-19468
    ERB-196 550997-55-2 99.89%
    ERB-196 is a nonsteroidal selective estrogen receptor-β (ERβ) agonist.
    ERB-196
  • HY-19477
    SB-616234-A 908601-49-0 98.14%
    SB-616234-A is a selective and orally bioavailable 5-HT1B receptor antagonist, with anxiolytic and antidepressant activity.
    SB-616234-A
  • HY-19496
    4-Butyl-alpha-agarofuran 272126-07-5 ≥98.0%
    4-Butyl-alpha-agarofuran (AF 5) is an anxiolytic and antidepressant agent. 4-Butyl-alpha-agarofuran a α-agarofuran derivative that can be isolated from Gharu-wood. 4-Butyl-alpha-agarofuran can be used for the research of neurological disease research.
    4-Butyl-alpha-agarofuran
  • HY-19627
    Naldemedine 916072-89-4 98%
    Naldemedine (S-297995) is an orally active μ-opioid receptor antagonist (PAMORA). Naldemedine shows potent binding affinities (Ki=0.34, 0.43, 0.94 nM, respectively) and antagonist activities (IC50=25.57, 7.09, 16.1 nM, respectively) for recombinant human μ-, δ-, and κ- opioid receptors. Naldemedine can be used in opioid-induced constipation (OIC) research. Naldemedine is predicted to bind to 3CLpro encoded by SARS-CoV2 genome.
    Naldemedine
  • HY-19686
    Ipsapirone 95847-70-4
    Ipsapirone (TVX Q 7821) is an anxiolytic compound and a 5-HT1A receptor partial agonist. Ipsapirone (TVX Q 7821) also exhibits 5-HT1A receptor antagonistic effect, and only at high doses it can also produce an inhibitory effect on 5-HT2 and the α1-adrenergic function.
    Ipsapirone
  • HY-19849
    BGC-20-1531 free base 736183-35-0 98.05%
    BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKB of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache.
    BGC-20-1531 free base
  • HY-19978
    RO-3 1026582-88-6
    RO-3 is a potent, CNS-penetrant, and orally active P2X3 and P2X2/3 antagonist with pIC50s of 5.9 and 7.0 for human homomultimeric P2X3 and heteromultimeric P2X2/3 receptors, respectively. RO-3 shows selectivity for P2X3 and P2X2/3 over all other functional homomultimeric P2X receptors (IC50 >10?μM at P2X1,2,4,5,7).
    RO-3
  • HY-21297
    3,5-Dihydroxy-2-naphthoic acid 89-35-0 98%
    3,5-Dihydroxy-2-naphthoic acid is a Naphthoic acid derivative. Naphthoic acid is a NMDA receptor allosteric modulator.
    3,5-Dihydroxy-2-naphthoic acid
  • HY-30006
    1-Aminocyclobutanecarboxylic acid 22264-50-2 ≥98.0%
    1-Aminocyclobutanecarboxylic acid is a NMDA receptor partial agonist acting at the glycine site, NR1.
    1-Aminocyclobutanecarboxylic acid
  • HY-50754
    gamma-secretase modulator 2 1093978-89-2 98.80%
    gamma-secretase modulator 2 is a potent and selective γ-secretase modulator for study of Alzheimer's disease.
    gamma-secretase modulator 2
  • HY-50889
    gamma-secretase modulator 3 1431697-84-5 ≥98.0%
    gamma-secretase modulator 3 is a gamma-secretase modulator.
    gamma-secretase modulator 3
  • HY-77491
    FAAH/MAGL-IN-5 1010096-65-7
    AM6701 is a potent FAAH/MAGL inhibitor (equipotent inhibitory IC50: 1.2 nM) with neuroprotective effects.
    FAAH/MAGL-IN-5
  • HY-A0118
    Naloxegol 854601-70-0 98%
    Naloxegol (NKTR-118; AZ-13337019) is a μ-opioid-receptor antagonist. Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract and effective for alleviating opioid-induced constipation.
    Naloxegol
Cat. No. Product Name / Synonyms Application Reactivity